Newron Pharmaceuticals S.p.A.
NP5
Rang în acțiuni
#17696
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Preț acțiune
$10.40
Capitalizare de piață
$212.64M
Schimbare (1 zi)
1.09%
Schimbare (1 an)
-41.83%
Țară
IT
Tranzacționează Newron Pharmaceuticals S.p.A. (NP5)
Categorie
Healthcare
Istoric al prețului acțiunii pentru Newron Pharmaceuticals S.p.A. (NP5)
Cel mai mare preț de închidere: $10.24 pe 2026-10-01
Cel mai mic preț de închidere: $31.91 pe 2015-07-01
Cel mai mic preț de închidere: $31.91 pe 2015-07-01
Istoric al prețului acțiunii pentru Newron Pharmaceuticals S.p.A. din 2015 până în 2026
Evoluția anuală a prețului acțiunii
| An | Performanță |
|---|---|
| 2026 (TTM) | -24.57% |
| 2025 | 182.46% |
| 2024 | 72.12% |
| 2023 | 283.57% |
| 2022 | -24.03% |
| 2021 | -24.86% |
| 2020 | -62.21% |
| 2019 | -18.66% |
| 2018 | -28.88% |
| 2017 | -55.22% |
| 2016 | -5.77% |
| 2015 | 0.00% |
Prețul acțiunii pentru companii similare sau concurente
| Companie | Preț acțiune | Variație 1an% | Țara |
|---|---|---|---|
| $536.47 | 25.80% |
US
|
|
| $187.21 | 597.24% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $883.47 | 8.51% |
NL
|
